Meanwhile, a study showed that the use of biologics (including IL-17 inhibitors) in psoriasis patients did not increase susceptibility to contracting COVID-19, severe disease progression, or increased hospitalization and mortality rates (56). This evidence concerns the gene IL17A and COVID-19.